Professorship for Multicenter Clinical Trials
At the CTH, we design, coordinate and conduct academic multicenter clinical trials on thrombotic disorders in collaboration with our European and overseas partners. Our research focuses on advancing and optimizing the risk-adjusted management of venous thromboembolism (VTE).
In ongoing prospective randomized and cohort trials we are investigating:
Stavros V. Konstantinides, MD, PhD, FESC
Medical Director of the CTH
CV Stavros Konstantinides(PDF 588,7 KB)
In ongoing prospective randomized and cohort trials we are investigating:
- advanced reperfusion strategies, including reduced-dose systemic thrombolysis or catheter-directed pharmacomechanical thrombus removal, for risk-adapted treatment of acute severe (intermediate-high-risk) pulmonary embolism
- identification of patients with low-risk pulmonary embolism who may be candidates for early discharge and home treatment
- approoaches to secondary VTE prevention beyond chronic oral anticoagulation, with a focus on modifying the patient’s global cardiovascular risk profile
- reliable, cost-effective algorithms for patient follow-up after pulmonary embolism, aiming at the prevention or early detection of severe late sequelae
- innovative strategies for de-escalation of postoperative primary thromboprophylaxis in parallel to the progress in surgical techniques and early patient mobilization.
Stavros V. Konstantinides, MD, PhD, FESC
Medical Director of the CTH
CV Stavros Konstantinides(PDF 588,7 KB)
A detailed overview of all ongoing and completed trials/projects is available on our website www.unimedizin-mainz.de/cth-clinical-trials.
Team - Clinical Trials
Professor Stavros Konstantinides, MD
Internal Medicine, Cardiology
Medical Director CTH
PD Dr. med. Dr. med. univ. Lukas Hobohm
Senior Physician, Cardiology I
Research Associate
Kai-Helge Schmidt, MD, PhD
Senior physician, Cardiology I
Research Associate
Stefano Barco, MD, PhD
Guest Scientist
Frederikus (Erik) Klok, MD, PhD
Professor of Internal Medicine
Leiden University Medical School, NL
Guest scientist
Selected original articles
- Valerio L, Mavromanoli AC, Barco S, […], Konstantinides SV, Rosenkranz S; FOCUS Investigators. Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. Eur Heart J 2022;43(36):3387-98
- Farmakis IT, Valerio L, Bikdeli B, […], Barco S. Annual mortality related to pulmonary embolism in the U.S. before and during the COVID-19 pandemic. J Am Coll Cardiol 2022;80(16):1579-81
- Hobohm L, Farmakis IT, Keller K, […], Konstantinides SV. Pulmonary embolism response team (PERT) implementation and its clinical value across countries: a scoping review and meta-analysis. Clin Res Cardiol 2022:1-11
- Sanchez O, Charles-Nelson A, Ageno W, […], Konstantinides SV, Meyer G; PEITHO Investigators. Reduced-dose intravenous thrombolysis for acute intermediate-high-risk pulmonary embolism: Rationale and design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial. Thromb Haemost 2022;122(5):857-66
- Klok FA, Toenges G, Mavromanoli AC, […], Meyer G, Konstantinides SV; PEITHO Investigators. Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial. Lancet Haematol 2021;8(9): e627-e636
- Barco S, Valerio L, Ageno W, […], Konstantinides SV. Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000-18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database. Lancet Respir Med 2021;9(1):33-42
- Barco S, Mahmoudpour SH, Valerio L, […], Konstantinides SV. Trends in mortality related to pulmonary embolism in the European Region, 2000-15: analysis of vital registration data from the WHO Mortality Database. Lancet Respir Med 2020;8(3):277-287
- Barco S, Schmidtmann I, Ageno W, […], Konstantinides SV, Lankeit M; HoT-PE Investigators. Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. Eur Heart J 2020;41(4):509-518
- Barco S, Mahmoudpour SH, Planquette B, Sanchez O, Konstantinides SV, Meyer G. Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review and meta-analysis. Eur Heart J 2019;40(11):902-910
- Barco S, Vicaut E, Klok FA, Lankeit M, Meyer G, Konstantinides SV; for the PEITHO Investigators. Improved identification of thrombolysis candidates amongst intermediate-risk pulmonary embolism patients: implications for future trials. Eur Respir J 2018;51(1). doi: 10.1183/13993003.01775-2017
- Konstantinides SV, Vicaut E, Danays T, Becattini C, Bertoletti L, Beyer-Westendorf J, […], Meyer G. Impact of thrombolytic therapy on the long-term outcome of intermediate-risk pulmonary embolism. J Am Coll Cardiol 2017;69(12):1536-1544
- Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, [….], Konstantinides S; PEITHO Investigators. Fibrinolysis for patients with acute intermediate-risk pulmonary embolism. N Engl J Med 2014;370(15): 1402-1411